(Q24246220)

PubMed

PubMed publication ID

16625536

26 November 2023

John K MacDonald

series ordinal

2

author given names

J K

author last names

Macdonald

1 reference

PubMed

PubMed publication ID

16625536

Cochrane Database of Systematic Reviews

26 November 2023

language of work or name

1 reference

19 April 2006

0 references

published in

0 references

cites work

Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Different therapy for different types of ulcerative colitis in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

An experiment to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

An oral preparation to release drugs in the human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Sulphasalazine in ulcerative colitis: in memoriam?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Kinetics of 5-aminosalicylic acid after jejunal instillation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Cortisone in ulcerative colitis; final report on a therapeutic trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Cortisone and corticotrophin in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Prospective, randomized, double-blind comparison of benzalazine and sulfasalazine in the treatment of active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Olsalazine in patients intolerant of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Olsalazine in the treatment of ulcerative colitis among patients intolerant of sulphasalazine: a prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Pentasa in lieu of sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Sulphasalazine and salicylazosulphadimidine in ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Therapeutic Efficacy of Sulfasalazine and Its Metabolites in Patients with Ulcerative Colitis and Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Absorption, metabolism, and excretion of salicylazosulfapyridine in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2

Olsalazine in active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000543.PUB2